Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Agouron deal

The companies will develop compounds intended to inactivate protease enzymes known to be required for replication of hepatitis C, viruses in the herpes family, and the rhinoviruses responsible for

Read the full 290 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE